OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S
Manufacturer: REVI plus sro, Akatova 503/13 Litomerice, I 27313778, Czech Republic
[PMID: 40569577] PubMed record related to this compound for laboratory literature review
~0.08mg 0.17mg 0.33mg 0.57mg 0.8mg 3x/week 3 injections/week P/T Ratio: ~1.5 Peak Reduction: 28% 4
Key Medication Classes and Documented Interaction Patterns Beyond glucose-lowering agents, semaglutide can interact with anticoagulants, certain cardiac medications, and GI-affecting drugs
Starting with CJC-1295/Ipamorelin, transitioning to sermorelin for maintenance: A patient uses CJC/Ipa to achieve target body composition and IGF-1 levels, then steps down to sermorelin for long-term maintenance with a lighter protocol